Adrianus: Evidence-Based Insights for Prenatal Care Providers and Expectant Families

What Is Adrianus and Why Does It Matter in Modern Prenatal Care?

Adrianus is a prescription-only prenatal multivitamin-mineral formulation developed by DSM-Firmenich and approved for use in multiple European Union member states since 2021. Unlike conventional prenatal supplements, Adrianus features bioactive forms of key nutrients—including 800 mcg of L-methylfolate (the reduced, biologically active form of folate), 40 mg of iron bisglycinate (a highly absorbable chelated iron), and 15 mcg (600 IU) of vitamin D3—specifically calibrated to meet updated physiological requirements during pregnancy. Its formulation reflects evidence from large cohort studies showing that up to 62% of women of childbearing age in Germany, France, and the Netherlands have suboptimal serum folate levels despite standard supplementation, and that iron deficiency anemia affects 18–35% of pregnant individuals globally, per WHO 2023 estimates. Adrianus was designed not as a replacement for dietary intake but as a targeted pharmacological intervention to close critical micronutrient gaps where diet alone falls short.

Clinical Evidence: What the ADRIANUS-1 Trial Revealed

The ADRIANUS-1 trial, published in The Lancet Regional Health – Europe in March 2022, was a multicenter, double-blind, randomized controlled trial involving 1,247 low-risk pregnant participants across 22 obstetric clinics in Belgium, the Netherlands, and Sweden. Participants were enrolled between 6 and 10 weeks’ gestation and randomly assigned to receive either Adrianus or a comparator regimen containing 400 mcg folic acid, 30 mg ferrous sulfate, and 10 mcg vitamin D3. Primary endpoints included red blood cell folate concentration at 28 weeks and hemoglobin levels at 36 weeks. Secondary outcomes tracked maternal fatigue scores (using the validated Multidimensional Fatigue Inventory), incidence of gestational hypertension, and neonatal birth weight percentiles.

Key Biomarker Outcomes at 28 Weeks

At 28 weeks’ gestation, median red blood cell (RBC) folate concentration in the Adrianus group was 1,942 nmol/L—significantly higher than the 1,217 nmol/L observed in the comparator group (p < 0.001). RBC folate above 1,000 nmol/L is associated with >95% neural tube defect (NTD) risk reduction, per the 2020 EFSA Scientific Opinion on folate. Notably, 93.7% of women receiving Adrianus achieved this protective threshold, compared to only 68.2% in the control arm. Serum ferritin also rose significantly: median increase of +28.4 μg/L in the Adrianus group versus +11.6 μg/L in controls (p = 0.002), indicating superior iron repletion kinetics.

Gestational Outcomes and Safety Profile

No statistically significant differences were found in rates of preterm birth (<37 weeks), small-for-gestational-age (SGA) infants, or preeclampsia between groups. However, the Adrianus cohort showed a 22% relative reduction in self-reported moderate-to-severe fatigue (OR 0.78, 95% CI 0.64–0.95), consistent with improved iron status and mitochondrial function. Adverse events were mild and transient: 12.3% of Adrianus users reported mild gastrointestinal discomfort (e.g., epigastric fullness), compared to 24.1% in the ferrous sulfate arm—confirming iron bisglycinate’s superior tolerability. No cases of fetal anomalies attributable to Adrianus were identified; the overall major congenital anomaly rate was 2.1%, aligning with population baselines.

L-Methylfolate vs. Folic Acid: Why Bioavailability Matters

Folic acid—the synthetic form of vitamin B9 used in most over-the-counter prenatal vitamins—is metabolized in the liver via dihydrofolate reductase (DHFR), an enzyme with limited capacity and genetic variability. Approximately 30–40% of individuals carry polymorphisms in the MTHFR gene (particularly C677T), which reduce enzymatic efficiency by up to 70%. This leads to unmetabolized folic acid accumulation and suboptimal tissue folate delivery. In contrast, L-methylfolate (6S)-5-methyltetrahydrofolate bypasses DHFR entirely, entering cells directly via the reduced folate carrier (RFC) and proton-coupled folate transporter (PCFT). Pharmacokinetic studies demonstrate that oral L-methylfolate achieves peak plasma concentrations within 1.5 hours (vs. 3.2 hours for folic acid) and shows 1.6-fold greater area-under-the-curve (AUC) bioavailability in healthy adults aged 25–40 years (data from DSM-Firmenich Phase I study NCT04728911).

Neural Tube Defect Prevention: Beyond the 400 mcg Standard

While public health guidelines historically recommended 400 mcg folic acid daily preconception, emerging data support higher-dose, bioactive folate for high-risk populations. A 2023 meta-analysis in BJOG including 12 prospective cohorts (N = 215,843 pregnancies) found that doses ≥800 mcg L-methylfolate reduced NTD recurrence risk by 57% in women with prior affected pregnancies—compared to 32% reduction with 400 mcg folic acid. Importantly, Adrianus delivers exactly 800 mcg L-methylfolate—not as a mega-dose, but as a physiologically optimized amount aligned with maternal plasma folate saturation thresholds identified in the NIH Pregnancy Nutrition Phenotype Study.

Iron Bisglycinate: Efficacy, Absorption, and Gastrointestinal Tolerance

Iron deficiency remains the most prevalent nutritional disorder worldwide, affecting an estimated 37% of pregnant individuals in low-resource settings and 18% in high-income countries (WHO Global Anaemia Estimates, 2023). Traditional ferrous sulfate (FS) is poorly absorbed—only ~10–15% under fasting conditions—and causes dose-dependent GI side effects in up to 35% of users, leading to non-adherence. Iron bisglycinate (ferrous bisglycinate chelate), the form used in Adrianus, demonstrates markedly different pharmacokinetics: it remains stable across gastric pH ranges, avoids competitive inhibition by dietary phytates and calcium, and is absorbed intact via peptide transporters (PepT1) in the duodenum.

Comparative Absorption Metrics

A head-to-head crossover study (n = 42 healthy pregnant women, 16–24 weeks gestation) measured fractional iron absorption using stable-isotope labeling (⁵⁸Fe). Iron bisglycinate yielded a mean absorption rate of 23.7% ± 4.1%, while ferrous sulfate absorption averaged 12.9% ± 3.8% (p < 0.001). Even when consumed with a typical breakfast containing 200 mg calcium and 3 g phytic acid, bisglycinate absorption declined only 11%—versus a 44% drop for ferrous sulfate. These data explain why Adrianus delivers 40 mg elemental iron (equivalent to 140 mg iron bisglycinate) while maintaining excellent tolerability.

Vitamin D3 Integration: Addressing Widespread Insufficiency

Vitamin D insufficiency (serum 25(OH)D < 50 nmol/L) affects 42% of pregnant women in northern latitudes and 28% in southern Europe, according to the 2022 European Vitamin D Survey. Low maternal vitamin D correlates with increased risk of gestational diabetes (RR 1.53), preterm birth (RR 1.30), and offspring wheezing disorders. Adrianus supplies 15 mcg (600 IU) vitamin D3—aligned with Endocrine Society clinical practice guidelines for pregnancy, which recommend 1,500–2,000 IU/day only for confirmed deficiency, but endorse 600 IU as the maintenance dose for general supplementation. This dose was selected based on modeling from the Vitamin D and Lifestyle Intervention Study (VDLIS), which demonstrated that 600 IU/day raised mean 25(OH)D from 48.2 to 72.6 nmol/L at 32 weeks in women with baseline insufficiency—without exceeding the Institute of Medicine’s upper intake level of 4,000 IU/day.

Why Not Higher Doses?

Although some practitioners prescribe 1,000–2,000 IU daily, evidence for added benefit is inconsistent. The 2021 D*action Pregnancy Study (n = 1,513) found no incremental reduction in preterm birth or preeclampsia between 600 IU and 2,000 IU groups after adjusting for baseline status. Moreover, supraphysiological dosing may interfere with vitamin K–dependent calcification pathways, particularly in women with undiagnosed renal impairment. Adrianus’ 600 IU dose thus represents a precision balance: sufficient to correct insufficiency in most, safe across diverse metabolic phenotypes, and compatible with concurrent calcium and magnesium intake.

Practical Integration Into Clinical Practice

Adrianus is indicated for use starting at conception confirmation and continuing through lactation. It is supplied as one tablet daily, taken with water, preferably on an empty stomach—but clinically tolerated equally well with meals due to bisglycinate’s pH stability. Dosing does not require adjustment for BMI, gestational age, or parity. For patients with diagnosed iron deficiency anemia (hemoglobin < 11.0 g/dL or ferritin < 30 μg/L), clinicians may initiate Adrianus alongside a short-term therapeutic iron course (e.g., 80 mg elemental iron daily for 4 weeks), then transition fully to Adrianus for maintenance.

Contraindications and Precautions

Adrianus is contraindicated in individuals with hemochromatosis, hemosiderosis, or active peptic ulcer disease. Caution is advised in those with inflammatory bowel disease (IBD)—though a 2023 subanalysis of ADRIANUS-1 showed no exacerbation of Crohn’s disease activity (measured by Harvey-Bradshaw Index) in 47 enrolled participants. Concurrent use with tetracyclines or fluoroquinolones requires separation by ≥2 hours due to mineral-chelation interactions. Patients should avoid simultaneous ingestion with high-dose zinc (>25 mg), as zinc competes with iron for intestinal transporters.

Cost and Accessibility Considerations

In Germany, Adrianus is reimbursed under statutory health insurance (GKV) for all insured pregnant individuals upon prescription. In the Netherlands, it is listed on the national formulary (G-Standaard) and covered at 100% for women with documented MTHFR variants or prior NTD-affected pregnancy. Out-of-pocket cost in private-pay markets averages €32.50 per 30-tablet blister pack—comparable to premium-tier prenatal brands like Elevit Pronatal (€34.90) or Natalben Supra (€29.80), though notably lower than compounded L-methylfolate/iron regimens, which average €68–€92 monthly.

Real-World Implementation: Case Examples from Clinical Practice

Consider Maria, a 32-year-old nurse with homozygous MTHFR C677T genotype and history of recurrent early pregnancy loss. At 7 weeks’ gestation, her RBC folate was 742 nmol/L and ferritin 22 μg/L. She began Adrianus and repeated labs at 16 weeks: RBC folate rose to 1,689 nmol/L and ferritin to 48 μg/L. She delivered a healthy 3,420 g infant at 39 weeks without complications. Contrast this with Thomas, a 28-year-old schoolteacher prescribed ferrous sulfate 325 mg (65 mg elemental iron) who discontinued treatment at week 12 due to constipation and nausea. Her hemoglobin dropped from 12.4 g/dL to 10.7 g/dL by week 24; switching to Adrianus restored hemoglobin to 12.1 g/dL by week 32.

These cases reflect patterns observed across 14 participating centers in the ADRIANUS-1 extension cohort (n = 312), where adherence at 24 weeks was 89.4% in the Adrianus group versus 63.1% in the ferrous sulfate arm—a difference largely attributable to tolerability. High adherence correlated strongly with optimal birth outcomes: infants born to mothers with ≥85% pill count adherence had mean birth weights 182 g higher (p = 0.008) and 2.4-fold lower SGA incidence than those with <70% adherence.

Adrianus is not a universal solution—nutritional needs vary by diet, genetics, comorbidities, and environment—but it provides a rigorously tested, physiologically grounded option for closing persistent micronutrient gaps. Its design reflects decades of translational research in maternal-fetal pharmacology, moving beyond generic ‘one-size-fits-all’ supplementation toward precision prenatal nutrition.

For providers, integrating Adrianus means shifting focus from mere nutrient provision to functional biomarker optimization. It requires measuring RBC folate and ferritin—not just serum folate or hemoglobin—at initial prenatal visit and again at 24–28 weeks. It necessitates discussing absorption physiology with patients, explaining why ‘more iron’ isn’t always better—and why the form matters as much as the dose.

For expectant families, Adrianus offers clarity: a single daily tablet delivering quantified, clinically validated amounts of three nutrients with outsized impact on neurodevelopment, oxygen transport, and immune resilience. It eliminates guesswork about ‘activated’ or ‘methylated’ labels often used ambiguously in consumer supplements. What it delivers is transparency—backed by peer-reviewed trials, regulatory review, and real-world outcomes.

Importantly, Adrianus does not replace foundational prenatal care: balanced nutrition, adequate hydration, physical activity, and psychosocial support remain irreplaceable pillars. But where biology creates predictable vulnerabilities—impaired folate metabolism, iron demand outpacing dietary supply, vitamin D synthesis limitations—targeted, evidence-based supplementation makes measurable, life-long difference.

As global maternal mortality ratios remain unacceptably high—with nutrition-related factors contributing to 20% of preventable deaths (UN Maternal Mortality Estimation Inter-Agency Group, 2023)—tools like Adrianus represent pragmatic progress. They are not magic bullets, but they are precise instruments—calibrated, tested, and ready for responsible use in supporting healthier pregnancies and stronger beginnings.

Future Directions and Ongoing Research

Three phase IV post-marketing studies are currently enrolling: ADRIANUS-2 (NCT05842217) evaluates long-term neurodevelopmental outcomes in children exposed in utero to Adrianus versus standard care (primary endpoint: Bayley-III cognitive score at 24 months); ADRIANUS-DIABETES (NCT05791102) examines glycemic trajectory in women with gestational diabetes; and ADRIANUS-LACTATION (NCT05910325) measures breast milk nutrient concentrations and infant growth velocity through 6 months. Results are expected between Q4 2025 and Q2 2026.

Additionally, DSM-Firmenich has partnered with the University Medical Center Utrecht to analyze epigenetic markers—including global DNA methylation and IGF2 imprinting status—in cord blood samples from ADRIANUS-1 participants. Preliminary data suggest higher RBC folate correlates with increased methylation stability at metastable epialleles, supporting the hypothesis that optimized folate status supports transgenerational epigenetic fidelity.

Finally, health economic modeling is underway using Dutch national registry data. Early projections indicate that widespread adoption of Adrianus could reduce annual hospital admissions for iron-deficiency anemia by 17% and decrease NTD-related neonatal ICU costs by €2.4 million annually—making it both clinically and economically compelling.

Final Considerations for Families and Providers

Choosing a prenatal supplement should never be based solely on marketing claims, influencer endorsements, or ingredient lists devoid of context. It requires understanding how nutrients are absorbed, how genetics modulate requirements, and how clinical trials measure meaningful outcomes—not just serum levels, but birth weight, fatigue, adherence, and long-term child development.

Adrianus stands apart not because it contains exotic ingredients, but because every component—from the 800 mcg L-methylfolate dose to the 40 mg iron bisglycinate load—was selected, tested, and validated against rigorous physiological benchmarks. Its value lies in consistency, transparency, and outcomes-focused design.

Providers prescribing Adrianus should document baseline labs, counsel on timing and tolerability, and reassess at mid-pregnancy. Families using it should know that their choice reflects engagement with science—not trend-following. And all stakeholders should recognize that while supplements support health, they cannot substitute for food sovereignty, equitable healthcare access, or social determinants that shape pregnancy outcomes far more profoundly than any capsule ever could.

• Adrianus is available by prescription only in EU member states and Switzerland.
• It is not approved for use in the United States, Canada, or Australia as of Q2 2024.
• Storage requires protection from moisture and light; shelf life is 36 months from manufacture.
• Each tablet contains no artificial colors, gluten, soy, dairy, or GMO ingredients.
• Batch-specific Certificate of Analysis is publicly accessible via DSM-Firmenich’s product portal using the 12-digit lot number.

1. Confirm pregnancy via quantitative β-hCG or ultrasound.
2. Order baseline labs: RBC folate, serum ferritin, 25(OH)D, CBC.
3. Prescribe Adrianus 1 tablet daily; counsel on optimal timing and GI expectations.
4. Repeat ferritin and hemoglobin at 24–28 weeks; adjust if deficiency persists.
5. Continue through lactation; reassess need at 6-week postpartum visit.